Scribe Therapeutics (NASDAQ:SCTX) Upgraded at Zacks Research

Scribe Therapeutics (NASDAQ:SCTX) was upgraded by equities researchers at Zacks Research to a “hold” rating in a research note issued on Tuesday, Zacks reports.

Other equities research analysts have also recently issued research reports about the company. Guggenheim started coverage on Scribe Therapeutics in a research note on Tuesday, August 18th. They issued a “buy” rating and a $50.00 price target for the company. Wall Street Zen upgraded Scribe Therapeutics to a “hold” rating in a report on Saturday, August 1st. Wells Fargo & Company started coverage on shares of Scribe Therapeutics in a report on Tuesday, August 18th. They set an “overweight” rating and a $60.00 price target for the company. Leerink Partners initiated coverage on shares of Scribe Therapeutics in a research report on Tuesday, August 18th. They issued an “outperform” rating and a $37.00 price target on the stock. Finally, HC Wainwright initiated coverage on shares of Scribe Therapeutics in a research report on Monday. They set a “buy” rating and a $60.00 price objective for the company. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $51.75.

Scribe Therapeutics Trading Up 6.6%

NASDAQ SCTX opened at $30.90 on Tuesday. Scribe Therapeutics has a twelve month low of $17.31 and a twelve month high of $39.60.

Scribe Therapeutics (NASDAQ:SCTX) last posted its quarterly earnings data on Wednesday, September 2nd. The company reported ($3.84) earnings per share for the quarter, beating analysts’ consensus estimates of ($6.20) by $2.36. On average, equities analysts expect that Scribe Therapeutics will post -6.72 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Scribe Therapeutics news, CFO David Parrot bought 2,666 shares of the stock in a transaction on Thursday, July 23rd. The stock was acquired at an average cost of $15.00 per share, for a total transaction of $39,990.00. Following the completion of the acquisition, the chief financial officer owned 1,333 shares in the company, valued at $19,995. This trade represents a -200.00% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, Director Carl L. Gordon purchased 1,000,000 shares of the company’s stock in a transaction on Monday, July 27th. The stock was acquired at an average cost of $15.00 per share, for a total transaction of $15,000,000.00. Following the completion of the purchase, the director owned 1,348,825 shares of the company’s stock, valued at approximately $20,232,375. This trade represents a 286.68% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders have acquired 3,727,237 shares of company stock valued at $56,291,746.

Trending Headlines about Scribe Therapeutics

Here are the key news stories impacting Scribe Therapeutics this week:

• Positive Sentiment: Quarterly loss beat expectations: Scribe reported a second-quarter 2026 loss of $3.84 per share, significantly narrower than the $6.20 loss analysts expected. The earnings surprise may have improved sentiment toward the clinical-stage biotechnology company. Scribe Therapeutics earnings press release
• Positive Sentiment: Pipeline advanced into human testing: The company initiated the first-in-human Phase 1 trial of STX-1150, an ultra-long-acting LDL-cholesterol-lowering therapy using its ELXR epigenetic silencing technology. The treatment is designed to avoid permanent genetic changes, potentially strengthening Scribe’s cardiovascular disease pipeline. Scribe Therapeutics second-quarter results and corporate highlights
• Positive Sentiment: Non-dilutive support and financing improved runway: Scribe received more than $25 million from the California Institute for Regenerative Medicine to advance STX-1200 and STX-1400. In addition, its upsized IPO, including the underwriters’ full option exercise, and a private placement to Sanofi generated approximately $155.5 million in gross proceeds. Management said available funding should support operations into the first half of 2029. Scribe Therapeutics financing and financial results
• Positive Sentiment: Analyst coverage was bullish: HC Wainwright began coverage with a “Buy” rating and a $60 price target, well above the stock’s recent trading level. The firm projects continued losses but expects quarterly losses to narrow after 2026.
• Neutral Sentiment: Management also announced participation in upcoming investor conferences, which could provide additional visibility for Scribe’s technology and clinical programs but does not itself change the company’s fundamentals. Scribe Therapeutics investor conference announcement
• Negative Sentiment: Scribe remains unprofitable, with HC Wainwright forecasting a $6.72 per-share loss for fiscal 2026 and a $4.90 loss for fiscal 2027. Continued clinical spending and the recently issued equity could also create ongoing dilution and volatility risks.

Scribe Therapeutics Company Profile

Scribe Therapeutics Inc is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Scribe Therapeutics Inc is based in ALAMEDA, Calif.